137 related articles for article (PubMed ID: 19472531)
21. Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis.
Okamoto H; Nomura M; Nakaya Y; Uehara K; Saito K; Kimura M; Chikamori K; Ito S
Intern Med; 2003 Aug; 42(8):655-64. PubMed ID: 12924487
[TBL] [Abstract][Full Text] [Related]
22. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
Ramirez MA; Borja NL
Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
[TBL] [Abstract][Full Text] [Related]
23. [Current advances in the treatment of diabetes mellitus].
Ohta M
Nihon Ika Daigaku Zasshi; 1999 Jun; 66(3):195-8. PubMed ID: 10401238
[No Abstract] [Full Text] [Related]
24. Cardiac sympathetic neuropathy and effects of aldose reductase inhibitor in streptozotocin-induced diabetic rats.
Kurata C; Okayama K; Wakabayashi Y; Shouda S; Mikami T; Tawarahara K; Sugiyama T
J Nucl Med; 1997 Nov; 38(11):1677-80. PubMed ID: 9374332
[TBL] [Abstract][Full Text] [Related]
25. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan.
Hotta N; Sakamoto N; Shigeta Y; Kikkawa R; Goto Y
J Diabetes Complications; 1996; 10(3):168-72. PubMed ID: 8807467
[TBL] [Abstract][Full Text] [Related]
26. Aldose reductase structures: implications for mechanism and inhibition.
El-Kabbani O; Ruiz F; Darmanin C; Chung RP
Cell Mol Life Sci; 2004 Apr; 61(7-8):750-62. PubMed ID: 15095000
[TBL] [Abstract][Full Text] [Related]
27. [Pathophysiology and treatment for diabetic neuropathy].
Yasuda H
Rinsho Shinkeigaku; 2009 Apr; 49(4):149-57. PubMed ID: 19462812
[TBL] [Abstract][Full Text] [Related]
28. [SG-210].
Akira T; Naka H
Nihon Rinsho; 1997 Nov; 55 Suppl():216-20. PubMed ID: 9434470
[No Abstract] [Full Text] [Related]
29. [Diabetic neuropathy--concept, staging, diagnosis, treatment].
Ida M; Kuroiwa Y
Nihon Rinsho; 2002 Oct; 60 Suppl 10():191-7. PubMed ID: 12430228
[No Abstract] [Full Text] [Related]
30. Effectiveness of aldose reductase inhibitors for diabetic gastroenteropathy with constipation.
Nakamura T; Okano R; Uchiyama H; Seo Y; Okuda S
Intern Med; 1997 Jul; 36(7):479-83. PubMed ID: 9240496
[TBL] [Abstract][Full Text] [Related]
31. [Research progress in aldose reductase].
Gu J; Yan J; Wu W; Huang Q; Ouyang D
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Apr; 35(4):395-400. PubMed ID: 20448367
[TBL] [Abstract][Full Text] [Related]
32. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications.
Kador PF; Kinoshita JH; Sharpless NE
J Med Chem; 1985 Jul; 28(7):841-9. PubMed ID: 3925146
[No Abstract] [Full Text] [Related]
33. Epalrestat improves diabetic wound healing via increased expression of nerve growth factor.
Nakagaki O; Miyoshi H; Sawada T; Atsumi T; Kondo T; Atsumi T
Exp Clin Endocrinol Diabetes; 2013 Feb; 121(2):84-9. PubMed ID: 23426701
[TBL] [Abstract][Full Text] [Related]
34. [Diabetic neuropathy].
Yagihashi S
Nihon Rinsho; 2006 Sep; Suppl 3():155-60. PubMed ID: 17022522
[No Abstract] [Full Text] [Related]
35. Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus.
Steele JW; Faulds D; Goa KL
Drugs Aging; 1993; 3(6):532-55. PubMed ID: 8312678
[TBL] [Abstract][Full Text] [Related]
36. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
Yoshida T; Nishioka H; Yoshioka K; Nakano K; Kondo M; Terashima H
Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
[TBL] [Abstract][Full Text] [Related]
37. Drug therapy of diabetic neuropathy.
Brooks PJ; Francisco GE
Clin Podiatr Med Surg; 1992 Apr; 9(2):257-74. PubMed ID: 1586903
[TBL] [Abstract][Full Text] [Related]
38. ["Diabetic autonomic neuropathy" series. Epidemiology, pathogenesis, basic therapy and prognosis].
Luft D
MMW Fortschr Med; 2002 May; 144(20):47-50. PubMed ID: 12119885
[No Abstract] [Full Text] [Related]
39. Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus.
Ikeda T; Iwata K; Tanaka Y
Diabetes Res Clin Pract; 1999 Mar; 43(3):193-8. PubMed ID: 10369429
[TBL] [Abstract][Full Text] [Related]
40. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
Shindo H; Tawata M; Aida K; Onaya T
J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
